Genmab - ADR Stock News

Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.

Genmab shares have doubled in three months after three successful Phase 3 cancer drug trials in October. The Danish biotech is using royalty income from drugs such as Darzalex to fund a shift toward owning more of the medicines it develops and sells.

Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.

Company Announcement COPENHAGEN, Denmark; October 28, 2026 Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing the risk of death by 50% in patients with PD-L1 positive head and neck squamous cell carcinoma (HNSCC), regardless of HPV status Genmab plans to engage global regulatory authorities and will submit fu...

The Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.

Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC), with responses observed across HPV-positive and HPV-negative disease Phase 3 program in 1L HNSCC is ongoing, with topline da...